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Abstract
Objective: To increase our understanding of the etiology of idiopathic thrombocytopenic purpura (ITP) 
some cytokine gene polymorphisms were analyzed for susceptibility to the disease. The aim of this 
study was to investigate the role of tumor necrosis factor-alpha (TNF-α) -308 G/A and transforming 
growth factor-beta 1 (TGF-β1) –915 G/C polymorphisms in the development and clinical progression 
of childhood ITP .
Materials and Methods: In all, 50 pediatric patients with ITP (25 with acute ITP and 25 with chronic 
ITP) and 48 healthy controls were investigated via LightCycler® PCR analysis for TNF-α -308 G/A and 
TGF-β1 -915 G/C polymorphisms.
Results: The frequency of TNF-α -308 G/A polymorphism was 20%, 16%, and 22.9% in the acute ITP 
patients, chronic ITP patients, and controls, respectively (p>0.05). The frequency of TGF-β1 -915 G/C 
polymorphism was 16%, 8%, and 8.3% in the acute ITP patients, chronic ITP patients, and controls, 
respectively (p>0.05). The risk of developing ITP and clinical progression were not associated with 
TNF-α -308 G/A (OR: 0.738, 95% CI: 0.275-1.981, and OR: 0.762, 95% CI: 0.179-3.249) or TGF-β1 -915 
G/C (OR: 1.5, 95% CI: 0.396-5.685, and OR: 0.457, 95% CI: 0.076-2.755) polymorphisms. 
Conclusion: The frequency of TNF-α -308 G/A and TGF-β1 -915 G/C polymorphisms did not differ 
between pediatric ITP patients and healthy controls, and these polymorphisms were not associated with 
susceptibility to the development and clinical progression of the disease. (Turk J Hematol 2011; 28: 170-5)
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Idiopathic  thrombocytopenic  purpura  (ITP)  is 
one of the most frequent causes of acquired throm-
bocytopenia and is characterized by destruction of 
autoantibody-mediated platelets. The pathophysiol-
ogy of ITP is complex and includes antibodies, cyto-
kines, antigen-presenting cells, co-stimulatory mol-
ecules, and T- and B-lymphocytes. When autoreac-
tive B-lymphocytes produce anti-platelet antibodies, 
T-lymphocytes play an important role in this autoim-
mune process [1-3].
Children with ITP have a Th1-type cytokine pat-
tern with elevated levels of tumor necrosis factor-
alpha (TNF-α), as in most autoimmune diseases [4]. 
Researches have shown that polymorphisms in the 
TNF-α gene at position -308 and -238 affect gene tran-
scription with increased TNF-α production [5,6]. The 
transcriptionally more active allele of TNF-α (allele 2 
of  -308)  was  less  frequently  observed  in  pediatric 
chronic ITP patients than in healthy controls [7]. 
Transforming  growth  factor-beta  1  (TGF-β1)  is 
another multifunctional cytokine that plays a critical 
role  in  the  pathogenesis  of  inflammatory,  autoim-
mune,  and  malignant  diseases.  The  expression  of 
TGF-β1 is influenced by polymorphisms in the TGF-
β1 gene, which may be partly relevant to certain dis-
eases [8-10]. It was reported that some TGF-β1 poly-
morphisms are not associated with the development 
and  progress  of  ITP  [11].  The  aim  of  the  present 
study was to determine if TNF-α -308 G/A and TGF-β1 
-915 G/C polymorphisms play a role in the develop-
ment and clinical progression of ITP in children.
Materials and Methods
Study population
The study was conducted at Ankara University, 
Faculty  of  Medicine,  Department  of  Pediatric 
Hematology,  Pediatric  Molecular  Pathology  and 
Genetics Division, and at Ankara Dışkapı Children’s 
Health Training and Research Hospital, Department 
of  Pediatric  Hematology.  In  all,  50  pediatric  ITP 
patients (25 acute ITP and 25 chronic ITP) and 48 
healthy controls were enrolled in this study. Children 
diagnosed with acute or chronic ITP and regularly 
followed-up  in  the  hospitals  participating  in  the 
study were considered for inclusion. 
The diagnosis of ITP was based on medical history, 
physical  examination,  and  thrombocytopenia. 
Thrombocytopenia that resolved within 6 months of 
onset was defined as acute ITP and thrombocytope-
nia  that  persisted  for  >6  months  was  defined  as 
chronic ITP . All the controls had a negative history of 
thrombocytopenia and ITP , and their blood samples 
were obtained from the DNA bank of Ankara University, 
Faculty  of  Medicine,  Department  of  Pediatric 
Hematology,  Pediatric  Molecular  Pathology  and 
Genetics Department. Informed consent was obtained 
from all the patients, the controls, and their parents. 
The  study  protocol  was  approved  by  the  Ankara 
University Faculty of Medicine Ethics Committee.
Genomic DNA analysis, and TNF-α -308 G/A and 
TGF-β1 -915 G/C polymorphism genotyping
Peripheral blood samples were obtained from all 
the participants. Blood samples were collected in 
Özet
Amaç: İdiopatik trombositopenik purpura (ITP)’nın etyolojisini anlayabilmek için, hastalığa yatkınlık 
üzerinde bazı sitokin gen polimorfizmleri incelenmiştir. Bu çalışmanın amacı çocukluk çağı ITP’sinin 
gelişimi ve klinik seyrinde tümör nekrozis faktör-alfa (TNF-α) –308G/A ve transforming growth faktör-
beta1 (TGF-β1) -915G/C polimorfizmlerinin rolünü araştırmaktır.
Yöntem ve Gereçler: Elli ITP’li çocuk hasta (25 akut ITP , 25 kronik ITP) ve 48 sağlıklı kontrol TNF-α–
308G/A ve TGF-β1–915G/C polimorfizmleri için Light Cycler PCR analizi ile araştırıldı.
Bulgular: Akut ITP , kronik ITP ve kontrollerde TNF-α–308G/A polimorfizm sıklığı sırasıyla %20, %16 ve 
%22.9 (p>0.05), ve TGF-β1–915G/C polimorfizm sıklığı sırasıyla %16, %8 ve %8.3 (p>0.05) idi. ITP 
gelişim riski ve klinik seyri ile TNF-α–308G/A (OR: 0.738, %95 Cl: 0.275-1.981 ve OR: 0.762, %95 Cl: 
0.179-3.249) ve TGF-β1–915G/C (OR: 1.5, %95 Cl: 0.396-5.685 ve OR: 0.457, %95 Cl: 0.076-2.755) 
polimorfizmleri arasında ilişki bulunamadı.
Sonuç: Bu sonuçlar, çocukluk çağı ITP hastalarında TNF-α–308G/A ve TGF-β1–915G/C polimorfizmleri-
nin sıklığının sağlıklılardan farklı olmadığını göstermiş olup, bu polimorfizmlerin ITP gelişimi ve hastalı-
ğın klinik seyri için risk oluşturmadığını düşündürmektedir. (Turk J Hematol 2011; 28: 170-5)
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Geliş tarihi: 24 Mayıs 2010   Kabul tarihi: 14 Aralık 2010 
Okulu et al.
Polymorphisms in childhood ITP Turk J Hematol 2011; 28: 170-5 171microfuge  tubes  containing  ethylenediamine  tet-
raacetic acid as anticoagulant. Genomic DNA was 
extracted from peripheral blood leukocytes using 
the phenol-chloroform method.
TNF-α -308 polymorphism
Regions  containing  TNF-α  -308  G/A  polymor-
phisms were amplified via polymerase chain reac-
tion  (PCR)  using  0.1  μg/mL  concentration  of  2 
primer sets, according to our previous report [12].
TGF-β1 -915 polymorphism 
Regions  containing  TGF-β1  -915  G/C  polymor-
phisms  were  amplified  via  PCR  using  0.1  μg/mL 
concentration of 2 primer sets. The primer sequenc-
es used for the TGF-β1 -915 promoter region were 
as follows:
Forward: 5’-ACC ACA CCA GCC CTG TTC GC-3’; 
Reverse: 5’-AGC TTG GAC AGG ATC TTG CC-3’. 
PCR yielded a 224-base pair (bp) long oligonu-
cleotide product and the results were confirmed 
based on 2% agarose gel electrophoresis contain-
ing 0.5 mg/mL ethidium bromide at 100 W for 45 
min using an 18-μL PCR product. The gels were 
evaluated with a UV transilluminator imaging ana-
lyzer. 
Statistical analysis
Statistical  analysis  was  performed  using  SPSS 
v.15.0 (Statistical Package for Social Sciences, Inc., 
Chicago,  IL,  USA).  The  demographic  features  of 
the acute and chronic ITP patients were compared 
using Student’s t-test and the Mann-Whitney U-test. 
The odds ratio and 95% confidence interval (CI), 
as estimates of the relative risk of allele frequency, 
were  calculated  for  the  entire  study  population. 
The 95% CI was calculated based on a conditional 
logistic regression algorithm using the maximum 
likelihood method.
Results
In the present study 50 ITP patients (25 acute ITP 
and 25 chronic ITP) and 48 controls were analyzed 
for TNF-α -308 G/A and TGF-β1 -915 G/C polymor-
phisms. The demographics of the acute and chronic 
ITP patients are shown in Table 1. The acute ITP 
patients were aged 4 months to 12 years (median 
age:  6  years),  and  the  chronic  ITP  patients  were 
aged 18 months to 15.5 years (median age: 9 years). 
The  patients  with  chronic  ITP  were  significantly 
older (p<0.05). Hemoglobin, leukocyte, and plate-
let counts in the acute and chronic ITP patients at 
admission did not differ significantly (p=0.12, 0.99, 
and 0.64, respectively). 
In total, 5 (20%) of the 25 acute ITP patients, 4 
(16%) of the 25 chronic ITP patients, and 11 (22.9%) 
of the 48 control subjects had TNF-α -308 G/A gene 
polymorphism.  The  frequency  of  TNF-α  -308  G/A 
gene polymorphism in the acute ITP , chronic ITP , 
and  control  groups  did  not  differ  significantly 
(p>0.05). In addition, the A allele frequency did not 
differ significantly between the 3 groups (p>0.05). 
The frequency of TGF-β1 -915 G/C polymorphism 
in the acute ITP , chronic ITP , and control groups was 
16%, 8%, and 8.3%, respectively, but the difference 
was not significant (p>0.05). C allele frequency was 
2-fold higher in the acute ITP patients (8%) than in 
the chronic ITP patients (4.1%) and controls (4%); 
the  difference  was  not  statistically  significant 
(p>0.05).  The  distribution  of  TNF-α  -308  G/A  and 
TGF-β1 -915 G/C polymorphisms in the study and 
control groups are shown in Tables 2 and 3.
The risk of developing ITP was not associated 
with TNF-α -308 G/A (OR: 0.738, 95% CI: 0.275-1.981) 
or TGF-β1 -915 G/C (OR: 1.5, 95% CI: 0.396-5.685) 
polymorphisms. The frequency of TNF-α -308 G/A 
and TGF-β1 -915 G/C polymorphisms in the acute 
and chronic ITP patients did not differ significantly 
Okulu et al.
Polymorphisms in childhood ITP Turk J Hematol 2011; 28: 170-5 172
Table 1. Patient demographics 
  Acute ITP   Chronic ITP  p 
  (n=25)  (n=25) 
Age (years)  5.6±3.5  8.0±3.9  0.028
Sex (M/F)  15/10  11/14  >0.05
Hemoglobin (g/dl)*  11.5 (8.0-14,9)  11.9 (6.8-14.5)  >0.05
Leukocyte (/mm3)*  8400 (4900-17300)  8100 (5000-23900)  >0.05
Platelet (/mm3)*  8000 (1000-25000)  8000 (1000-78000)  >0.05
*Results are expresed as median (range)(p>0.05), and these polymorphisms did not have an 
affect  on  chronic  progression  of  the  disease   
(OR: 0.762, 95% CI: 0.179-3.249 and OR: 0.457, 95% 
CI: 0.076-2.755, respectively).
Discussion
 
Although the etiology of ITP remains unclear, it is 
generally  accepted  that  both  environmental  and 
genetic factors play an important role in the devel-
opment of the disease [13,14]. Many recent studies 
have  focused  on  the  association  between  some 
cytokine gene polymorphisms and susceptibility to 
ITP . Studies that investigated genetic risk factors in 
the  pathogenesis  of  ITP  reported  that  polymor-
phisms  of  HLA  class  II  antigens,  FcγRIIA  and 
FcγRIIIA, and human platelet antigen (HPA) systems 
were associated with the development of ITP and 
response to treatment [7,15-19].
TNF-α is a pleiotropic cytokine produced primar-
ily by macrophages and T-cells, and has a range of 
inflammatory  and  immunomodulatory  activity   
[20-22]. Polymorphisms of TNF-α promoter are asso-
ciated with high levels of TNF-α and have been stud-
ied as a determinant of susceptibility to numerous 
diseases [12,21-25]. A study that examined inflam-
matory cytokines and Fcγ receptor polymorphisms in 
chronic childhood ITP reported that polymorphisms 
in 2 low-affinity FcγR genes (IIIA and IIIB) and 2 pro-
inflammatory cytokine genes (TNF and LTA) were 
associated  with  chronic  childhood  ITP  [7].  To  the 
best of our knowledge the role of TNF-α -308 G/A 
polymorphism in the development and progression 
of ITP has not been previously studied.
TGF-β is a multifunctional cytokine and TGF-β1 is 
the  most  abundant  isoform  [26,27].  TGF-β1  gene 
polymorphisms that alter TGF-β1 production have 
been studied in predicting susceptibility to certain 
diseases [8,9]. A significant increase in the percent-
age  of  NK  cells  and  elevated  TGF-β1  levels  have 
been observed in chronic ITP patients in remission 
[28]. Although it has been shown that TGF-β1 gene 
polymorphisms (509 G/C, codon 25, and codon 10) 
were  significantly  correlated  with  many  diseases 
and TGF-β1 production, the only study on the role of 
these polymorphisms in the pathophysiology of ITP 
reported  that  they  weren’t  correlated  with  the 
development,  clinical  progression,  or  treatment 
response of the disease [11,29-32]. 
In the present study the genotype frequency of 
TNF-α -308 G/A and TGF-β1 -915 G/C polymorphisms 
was evaluated in terms of their correlation with sus-
ceptibility to the development and progression of 
ITP . At the time of diagnosis it is not possible to pre-
dict the progress of the disease. To date, no prog-
nostic factors for the development and clinical pro-
gression  of  the  disease  have  been  reported  [33]. 
The results of the present study show that the fre-
quency of TNF-α -308 G/A and TGF-β1 -915 G/C poly-
morphisms in the acute ITP , chronic ITP , and control 
groups did not differ significantly. Moreover, associ-
ations  between  these  polymorphisms,  and  the 
development and clinical progress of ITP were not 
observed.
Plasma TNF-α and TGF-β1 levels in the patient 
and control groups were not analyzed in the present 
study. It is known that a substitution at the -308 posi-
tion  of  TNF-α  results  in  increased  production  of 
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Table 2. Distribution of TNF-α-308G/A polymorphism in ITP , acute ITP , chronic ITP patients and controls
Genotype   Controls  ITP patients  Acute ITP  Chronic ITP  Fischer’s  OR (95% CI) 
frequency  n=48  n=50  n=25  (n=25)  exact test 
  n (%)  n(%)  n (%)  n (%)   
G/G  37 (77.1)  41 (82)  20 (80)  21 (84)  0.546a  0.738 (0.275-1.981)
G/A  11 (22.9)  9 (18)  5 (20)  4 (16)  1.000b  0.762 (0.179-3.249)
OR Odds ratio; CI confidence interval, aITP group compared with the controls, bAcute ITP group compared with chronic ITP group
Table 3. Distribution of TGF-β1-915G/C polymorphism in ITP , acute ITP , chronic ITP patients and controls
Genotype  Controls  ITP patients  Acute ITP  Chronic ITP  Fischer’s  OR (95% CI) 
frequency  n=48  n=50  n=25  n=25  exact test 
  n (%)  n (%)  n (%)  n (%)   
G/G  44 (91.7)  44 (88)  21 (84)  23 (92)  0.741a  1.5 (0.396-5.685)
G/C  4 (8.3)  6 (12)  4 (16)  2 (8)  0.667b  0.457 (0.076-2.755)
OR Odds ratio; CI confidence interval, aITP group compared with the controls, bAcute ITP group compared with chronic ITP groupTNF-α [6], and that polymorphisms at codon 10 and 
25 of the TGF-β1 gene are involved in the upregula-
tion  of  TGF-β1  secretion.  Other  studies  failed  to 
observe  any  association  between  serum  TGF-β1 
levels and these polymorphisms [34]. 
In conclusion, TNF-α -308 G/A and TGF-β1 -915 
G/C polymorphisms did not play an important role as 
genetic risk factors for the development and progres-
sion of ITP . As the study and control groups were 
small, different results may be obtained by additional 
research involving larger patient populations. 
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